SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Celgene-CELG
An SI Board Since August 1996
Posts SubjectMarks Bans Symbol
804 71 0 CELG
Emcee:  rkrw Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
679From YMB 1: J Neurosci. 2006 Mar 1;26(9):2467-73. Related Thalidomide ansim1-3/8/2006
678Clinical Data Evaluating CC-10004 as New Oral Therapy in Severe Psoriasis Mondaysim1-3/6/2006
677Merrill: Celgene Corporation (CELG, $39.37, C-1-9) Reiterate Buy. Raising PT totom pope-3/3/2006
676[Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neurtuck-1/20/2006
675Wait for a Second Bite at Celgene By Dan Fitzpatrick RealMoney.com Contributor 1RealMuLan-1/12/2006
674THALOMID(R) Pivotal Phase III Multiple Myeloma Trial Reaches Pre-Specified Intersim1-1/9/2006
673Company Puts a Big Price Tag On Drug to Treat Blood Disease Message 22011007Doc Bones-12/29/2005
672Merrill: Revlimid Approved for MDS 5Q The FDA has approved Revlimid for the ttom pope-12/28/2005
671Celgene Corporation Announces Two-For-One Stock Split SUMMIT, N.J., Dec. 27 /PRsim1-12/28/2005
670FDA Grants REVLIMID(R) NDA Approval SUMMIT, N.J., Dec. 27 /PRNewswire-FirstCallsim1-12/28/2005
669I must admit, that after several blistering setbacks, i.e., KOSN, RIGL, etc.,whilarrytioga-12/27/2005
668Revlimid approved for MDS, launch expense to cause 2005 eps to miss current guidtuck-12/27/2005
667[Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexametuck-12/22/2005
666Lenalidomide + Dex for multiple myeloma Message 21963642John McCarthy-12/11/2005
665Here is press release (today) about VELCADE. New Data Show Median 30-Month SurvJohn McCarthy-12/11/2005
664Revlimid(R) Improves Overall Survival and Delays Time to Disease Progression in John McCarthy-12/11/2005
663Thalidomide reached "my" pick sale of $400 M, and still going strong aMiljenko Zuanic-11/3/2005
662<<In theory -- but just in theory -- this is a reasonable worry.>> Miljenko Zuanic-10/9/2005
661WSJ editorial blasts Pazdur again: <i>[The people who write the WSJ editDewDiligence_on_SI-10/8/2005
660REVLIMID(R) PDUFA Date Extended Three Months By FDA Monday October 3, 7:18 am ETsim1-10/3/2005
659UPDATE 1-Celgene expects Revlimid trial to resume quickly Wed Sep 28, 2005 11:39sim1-9/28/2005
658Revlimid trial halted due to higher incidence of DVT -- protocol being redone totuck-9/28/2005
657F.D.A. Advisory Panel Backs an Anemia Drug By ANDREW POLLACK [NYT] September 1sim1-9/15/2005
656FDA Oncologic Drugs Advisory Committee Recommends REVLIMID(R) for Full Approval sim1-9/14/2005
655US panel supports Celgene anemia drug Revlimid Wed Sep 14, 2005 12:04 PM ET BETHsim1-9/14/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News